Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: An extended Mayo Clinic prospective 63-month experience

Renal Failure

Volumn 30, Issue 4, 2008, Pages 363-371

  Onuigbo, Macaulay A C ^a,b   Onuigbo, Nnonyelum T C ^c  

^a MAYO CLINIC   (United States)

^b Mayo Health System   (United States)

^c NT Systems   (United States)

Author keywords

Chronic kidney disease; ESRD; Hypertension; RAAS blockade; Renal artery stenosis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CLONIDINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LISINOPRIL; METHYLDOPA; MINOXIDIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CAUCASIAN; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; STOMACH CANCER;

AGED; AGED, 80 AND OVER; AGING; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GERIATRIC ASSESSMENT; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL ARTERY OBSTRUCTION; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 45749093453     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220801947363     Document Type: Article

References (44)

1. Onuigbo M, Weir MR. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes Obes Metab. 2003;5(1):13-26.
2. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 327(10):685-691, 1992. Erratum in: N Engl J Med. 1992;327(24):1768.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-1462. Erratum in: N Engl J Med. 1993;330(2):152.
4. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359-364.
5. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312-2318.
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
7. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.
8. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-1587.
9. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200):253-259. Erratum in: Lancet. 2000;356(9232):860.
10. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
12. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
13. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906.
14. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet. 2003;362(9386):759-766.
15. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
16. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155(8):829-837.
17. Carter BL, Malone DC, Ellis SL, Dombrowski RC. Antihypertensive drug utilization in hypertensive veterans with complex medication profiles. J Clin Hypertens (Greenwich). 2000;2(3):172-180.
18. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by U.S. office-based physicians. Hypertension. 2000;36(4):600-603.
19. Scarsi KK, Bjornson DC. The use of ACE inhibitors as renoprotective agents in Medicaid patients with diabetes. Ann Pharmacother. 2000;34(9):1002-1006.
20. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med. 2004;141(2):95-101.
21. Szczech LA, Lazar IL. Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD. Kidney Int. 2004;90 (Suppl.):S3-S7.
22. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause? Kidney Int. 2005;67(5):1684-1691.
23. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69:913-919.
24. Silas JH, Klenka Z, Solomon SA. Captopril induced reversible renal failure: A marker of renal artery stenosis affecting a solitary kidney. Br Med J (Clin Res Ed). 1983;286(6379):1702-1703.
25. Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J (Clin Res Ed). 1984;288(6420):844-845.
26. Jackson B, McGrath BP, Matthews PG, Wong C, Johnston C. Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension. 1986;8:650-654.
27. Kalra PA, Mamtora H, Holmes AM, Waldek S. Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Q J Med. 1990;77(282):1013-1018.
28. Devoy MAB, Tomson CR, Edmunds ME, Feehally J, Walls J. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med. 1992;232(6):493-498.
29. Raine AE. Angiotensin-converting enzyme inhibition and renovascular disease. Q J Med. 1990;77(282):997-999.
30. Thomas MC. Diuretics, ACE inhibitors and NSAIDs - the triple whammy. Med J Aust. 2000;172(4):184-185.
31. Boyd IW, Mathew TH, Thomas MC. Cox-2 inhibitors and renal failure: The triple whammy revisited. Med J Aust. 2000;173:274.
32. Descombes E, Fellay G. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency. Ren Fail. 2000;22(6):815-821.
33. Vachharajani TJ, Dacie JE, Yaqoob MM, et al. Detection of occult renovascular disease in unexplained chronic kidney disease. Int Urol Nephrol. 2005;37(4):793-796.
34. Schalekamp MA, Wenting GJ. Angiotensin converting enzyme inhibition in renovascular hypertension: Failure of the stenotic kidney. Lancet. 1984;1(8374):464.
35. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. N Eng J Med. 1983;308(7):373-376.
36. Wenting GJ, Tan-Tjiong HL, Derkx FH, de Bruyn JH, Man in't Veld AJ, Schalekamp MA. Split renal function after captopril in unilateral renal artery stenosis. Br Med J (Clin Res Ed). 1984:288(6421):886-890.
37. Jackson B, Matthews PG, McGrath BP, Johnston CI. Angiotensin converting enzyme inhibition in renovascular hypertension: Frequency of reversible renal failure. Lancet. 1984;1(8370):225-226.
38. Hollenberg NK. Angiotenisn-converting enzyme inhibition: Renal aspects. J Cardiovasc Pharmacol. 1985;7:S40-S44.
39. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
40. Schwartz GL, Textor SC. Early referral for chronic kidney disease: Good for those who need it, but who are they? Mayo Clin Proc. 2006;81(11):1420-1422.
41. Onuigbo MAC, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): A prospective thirty-month Mayo Health system Clinic experience. Med Sci Monit. 2005;11(10):CR462-CR469.
42. Onuigbo MAC, Onuigbo NTC. Late-onset renal failure from RAAS blockade. Kidney Int. 2006;70:1378-1379.
43. Jacobson HR. Ischemic renal disease: An overlooked clinical entity? Kidney Int. 1988;34:729-743.
44. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20(1):72-80.